Ulimorelin
Based on the favorable effects of ulimorelin on gastrointestinal function in animal experiments and small clinical studies, ulimorelin has progressed to randomized clinical trials for the treatment of diabetic gastroparesis or POI. In patients with diabetic gastroparesis, ulimorelin improved gastrointestinal symptoms, such as vomiting and loss of appetite, while there were no significant differences in improving gastrointestinal function between patients with IP who took ulimorelin and those who took placebo [32]. For this reason, efficacy and the risk of unexpected hypotension, its development for gastrointestinal indications has been discontinued [33].